Green Planet Bioengineering Reports Q1 2025 Loss Amid Ongoing Financial Challenges

Green Planet Bioengineering Co., Ltd. (PINK: GPLB) has reported its quarterly financial results for the three months ending March 31, 2025. The company is classified as a public reorganized shell corporation with no active business operations as of this date.

Positive Aspects:

• Common Stock: The company has 20,006,402 shares of common stock issued and outstanding, remaining consistent since December 31, 2024.
• Funding Support: The company continues to receive funding from a related party of the majority stockholder, which is crucial for covering operational expenses.

Negative Aspects:

• Financial Position: The company has total current liabilities of $471,974, with no current assets reported, leading to a total stockholders’ deficit of $(471,974).
• Net Loss: For Q1 2025, the company incurred a net loss of $(6,840), higher than the $(6,465) loss reported for the same period in 2024, reflecting ongoing operational challenges.
• Accumulated Deficit: The accumulated deficit has increased to $(1,101,594) as of March 31, 2025.
• Going Concern Doubt: The ability to continue as a going concern is raised due to the reliance on external funding and the absence of a business model generating revenue.

Key Statistics:

• Current Assets: $0
• Total Current Liabilities: $471,974
• Stockholders’ Deficit: $(471,974)
• Net Loss for Q1 2025: $(6,840)
• Number of Shares Outstanding: 20,006,402

In summary, Green Planet Bioengineering Co., Ltd. faces significant financial challenges as it continues to operate as a public shell corporation. The company's reliance on funding from related parties and the lack of productive business operations casts uncertainty on its future viability. Investors should weigh these risks carefully when considering their positions in the company's stock.